Summit Therapeutics says Phase III HARMONi-GI1 trial of ivonescimab in biliary tract cancer shows OS superiority vs AstraZeneca’s Imfinzi regimen

Ivonescimab remains investigational in Summit’s licensed territories, limiting near-term revenue impact outside China.

Summit Therapeutics said Phase III HARMONi-GI1 results for ivonescimab with chemotherapy in first-line advanced biliary tract cancer showed overall survival superiority versus AstraZeneca’s Imfinzi (durvalumab) regimen.

• Topline findings were disclosed Aug. 25, 2026; full data will be presented at ESMO 2026 on Oct. 25.
• The ivonescimab regimen beat durvalumab with chemotherapy on overall survival, supporting a potential competitive edge in this setting.
• Secondary readouts also favored ivonescimab, reinforcing broader clinical momentum beyond its earlier lung cancer focus.